Moreover, tumour-associated CD8 + T cells are interconnected with molecular subtype; the non-ASCL1/NEUROD1 subtypes have significantly more CD8 + T cells than those of the ASCL1/NEUROD1 subtypes, thus they can benefit more from immunotherapy. This evidence concerns the gene NEUROD1 and neoplasm.